News & Videos - ADURO BIOTECH INC.

...

...

...

...

NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shutterfly, Inc. (NASDAQ:SFLY), Aegion Corporation (NASDAQ:AEGN), Columbia Property Trust, Inc. (NYSE:CXP), Aduro Biotech, Inc. (NASDAQ:ADRO), IQVIA Holdings Inc. (NYSE:IQV), and Intelsat S.A. (NYSE:I), including updated fundamental summaries, consolidated fiscal reporting, and...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

BERKELEY, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today the appointment of five key opinion leaders to its scientific advisory board, who join four existing leading clinicians, researchers and scientists. Newly appointed members include: Thomas Gajewski, M.D., Ph.D., Darren Higgins, Ph.D., F. Stephen Hodi, M.D., Wiebe Olijve, Ph.D., and David H. Raulet, Ph.D. “We are...

BERKELEY, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced an exclusive license agreement with Stanford University for state-of-the-art neoantigen identification technology developed by Dr. Hanlee Ji, associate professor of medicine at Stanford. Aduro will leverage its proprietary live, attenuated double-deleted Listeria (LADD) immunotherapy platform to engineer personalized...

BERKELEY, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today a clinical collaboration with Merck (known as MSD outside the United States and Canada). The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of gastric cancer....

BERKELEY, Calif., Dec. 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 35 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2017, at 10:00 am Pacific Time. To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com . About Aduro...

BERKELEY, Calif. and OSS, The Netherlands, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that Hans van Eenennaam, Ph.D., chief operational officer and executive director of Aduro Biotech Europe, and John Dulos, Ph.D., principal scientist, will be honored tonight by the Intellectual Property Owners Education Foundation (IPOEF) as winners of the 43rd Inventor of the Year Award for...

Expected Filing of Investigational New Drug (IND) Application in 2017 Company to Host Conference Call Today to Provide Program Update, Including STELLAR, at 5:30 a.m. PT/ 8:30 a.m. ET BERKELEY, Calif. and OSS, The Netherlands, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that an anti-CD27 antibody developed by Aduro Biotech Europe and derived from its proprietary B-select...

BERKELEY, Calif. and OSS, The Netherlands, Dec. 03, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced the presentation of data from preclinical studies supporting the clinical development of the company’s proprietary monoclonal antibody (mAb) BION-1301, a humanized anti-APRIL (A PRoliferation-Inducing Ligand) antibody for the treatment of multiple myeloma. Data from these in vivo and in vitro...

BERKELEY, Calif., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on its clinical trials evaluating the LADD (live, attenuated double-deleted) immunotherapy platform, enabling patient enrollment to resume in all Aduro-sponsored clinical studies. “We are pleased to come to a rapid agreement...

Data Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Continues to Show Clinical Activity of CRS-207 Two Additional Poster Presentations Detailing Promising Preclinical Results of STING and pLADD Programs BERKELEY, Calif., Nov. 12, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced highlights from a poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held in National Harbor, Maryland on the...

BERKELEY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced that Tom Dubensky Jr., Ph.D., chief scientific officer of Aduro, presented today about the company’s personalized LADD technology at the Society for Immunotherapy of Cancer (SITC) distinct session titled New Cancer Immunotherapy Agents in Development being held in conjunction with the SITC annual meeting. LADD is Aduro's...

BERKELEY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today highlighted an oral presentation given by the company’s chief scientific officer, Thomas Dubensky Jr., Ph.D., at the 4th European Society of Medical Oncology (ESMO) Symposium on Immuno-Oncology held last week in Lausanne, Switzerland. The data, generated from multiple preclinical models, demonstrated important changes in the tumor microenvironment and the activation of acute and systemic tumor-specific...

BERKELEY, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the third quarter 2016. Net loss for the three months ended September 30, 2016 was $35.1 million, or $0.54 per share, and for the nine months ended September 30, 2016 net loss was $61.6 million, or $0.96 per share, compared to a net income of $0.6 million, or $0.01 per share, and net loss of $42.3 million, or $1.09 per share respectively, for the same periods in 2015. Cash,...

--Current Clinical Trial Patients Are Continuing to Receive LADD Treatment-- --Company to Host Conference Call Today at 6 a.m. PT/9 a.m. ET-- BERKELEY, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that trials with investigational agents based on its LADD (Listeria-based immunotherapy construct)...

BERKELEY, Calif., Oct. 23, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced that it will hold a conference call to provide a corporate update tomorrow, October 24, 2016, at 6:00 a.m. PT. To participate in the conference call, please dial (844) 309-0604 (domestic) or (574) 990-9932 (international) and refer to conference ID 4915023. Live audio of the conference call will be simultaneously webcast and will be available to members of the news media, investors and the...